Stephen J. Greene
YOU?
Author Swipe
View article: Cardiovascular Multimorbidity in Older Adults in the United States by Race and Sex
Cardiovascular Multimorbidity in Older Adults in the United States by Race and Sex Open
View article: Worsening versus advanced heart failure: Management and challenges
Worsening versus advanced heart failure: Management and challenges Open
Heart failure (HF) is a progressive condition marked by recurrent episodes of symptom exacerbation, leading to worsening cardiac function, increased hospitalization and mortality risk. Worsening HF (WHF) and advanced HF (AdvHF) represent t…
View article: HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics An Updated 2025 Report from the Heart Failure Society of America
HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics An Updated 2025 Report from the Heart Failure Society of America Open
View article: Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States
Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States Open
Aims This study compared characteristics of patients with heart failure (HF) prescribed vericiguat vs. eligible patients with HF not prescribed vericiguat, and sought to identify factors associated with vericiguat use in real-world setting…
View article: Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management
Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management Open
View article: Type 2 Diabetes Mellitus–Related Mortality in the United States, 1999 to 2023
Type 2 Diabetes Mellitus–Related Mortality in the United States, 1999 to 2023 Open
View article: The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment
The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment Open
The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone is indicated in the United States for use in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Results from the FIDELIO-DKD and FIGARO-DK…
View article: Real‐World Health Care Resource Utilization and Costs Associated With First‐Line Dronedarone Versus First‐Line Ablation in Adults With Atrial Fibrillation
Real‐World Health Care Resource Utilization and Costs Associated With First‐Line Dronedarone Versus First‐Line Ablation in Adults With Atrial Fibrillation Open
Background Rhythm control therapy with antiarrhythmic drugs (AADs) or catheter ablation is recommended for treatment of atrial fibrillation (AF). The impact of first‐line AAD therapy (including dronedarone) or ablation on health care resou…
View article: Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The <scp>VELOCITY</scp> study
Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The <span>VELOCITY</span> study Open
ClinicalTrials.gov NCT06195930.
View article: Get With The Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead
Get With The Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead Open
The Get With The Guidelines-Heart Failure program was developed in 2005 with the goal of bringing evidence-based guidelines in heart failure management into widespread clinical practice. The program includes workshops, webinars, tool kits,…
View article: Time for a new perspective on polypharmacy in heart failure
Time for a new perspective on polypharmacy in heart failure Open
View article: A multicenter pragmatic implementation study of AI-ECG-based clinical decision support software to identify low LVEF: Clinical trial design and methods
A multicenter pragmatic implementation study of AI-ECG-based clinical decision support software to identify low LVEF: Clinical trial design and methods Open
View article: Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis Open
GLP-1RAs reduce worsening HF events and the composite of CV death or worsening HF in HFpEF, particularly in patients with obesity or diabetes. These findings support their role as a promising therapy requiring further HFpEF-focused trials.
View article: Diuretic Potentiation Strategies in Acute Heart Failure
Diuretic Potentiation Strategies in Acute Heart Failure Open
View article: A Pragmatic Trial Evaluating the Impact of the Anumana Clinical Decision Support Tool for Guideline-Directed Management of Heart Failure (Act-Hf): Clinical Trial Design and Methods
A Pragmatic Trial Evaluating the Impact of the Anumana Clinical Decision Support Tool for Guideline-Directed Management of Heart Failure (Act-Hf): Clinical Trial Design and Methods Open
View article: Aldosterone and Potassium in Heart Failure: Overcoming This Major Impediment in Clinical Practice
Aldosterone and Potassium in Heart Failure: Overcoming This Major Impediment in Clinical Practice Open
Aldosterone is a key regulator of fluid and electrolyte balance in the body. It is often dysregulated in heart failure (HF) and is a key driver of cardiac remodelling and worse clinical outcomes. Potassium regulation is essential for norma…
View article: Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry Open
View article: Prognostic value of quality of life and functional status in patients with heart failure: a systematic review and meta-analysis
Prognostic value of quality of life and functional status in patients with heart failure: a systematic review and meta-analysis Open
View article: From Hospital to Home
From Hospital to Home Open
Heart failure (HF) is a leading cause of hospitalization in older adults. Patients are at high risk of readmission and death following hospitalization for HF. There is no standard approach of health care delivery during the hospital-to-hom…
View article: Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial
Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial Open
OBJECTIVE We evaluated the effect of long-term intensive metabolic control with hybrid closed-loop (CL) on residual C-peptide secretion and glucose control compared with standard insulin therapy in youth with type 1 diabetes over 48 months…
View article: Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart Failure
Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart Failure Open
Importance Kidney health has received increasing focus as part of comprehensive heart failure (HF) treatment efforts. However, the occurrence of clinically relevant kidney outcomes in contemporary populations with HF has not been well stud…
View article: On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of <scp>TRANSFORM‐HF</scp>
On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of <span>TRANSFORM‐HF</span> Open
Aim The TRANSFORM‐HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalization for heart failure (HF), but may have been impacted by non‐adherence to the randomized diuretic. The curre…
View article: Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Clinical outcome results from the CHART-HF study
Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Clinical outcome results from the CHART-HF study Open
HFrEF patients with recent WHFE consistently had worse clinical outcomes in these non-clinical trial cohorts. Despite advances in therapies, unmet need to improve clinical outcomes in HFrEF patients with WHFE remains.
View article: Treatment patterns of patients with worsening heart failure with reduced ejection fraction
Treatment patterns of patients with worsening heart failure with reduced ejection fraction Open
Aims Patients with HFrEF and worsening HF events (WHFE) are at particularly high risk and urgently need disease‐modifying therapy. CHART‐HF assessed treatment patterns and reasons for medication decisions among HFrEF patients with and with…
View article: Impact of Insurance Status and Region on Angiotensin Receptor–Neprilysin Inhibitor Prescription During Heart Failure Hospitalizations
Impact of Insurance Status and Region on Angiotensin Receptor–Neprilysin Inhibitor Prescription During Heart Failure Hospitalizations Open
Among patients hospitalized between 2017 and 2020 for HFrEF who were prescribed RAS inhibitor therapy at discharge, insurance status, geographic region, and self-reported race were associated with ARNI initiation.
View article: Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure
Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure Open
In this nationwide U.S. cohort of patients hospitalized for newly diagnosed HFrEF, >4 of 5 patients were projected as eligible for quadruple therapy at discharge; yet, <1 in 6 were prescribed it. If clinical trial benefits can be fully rea…
View article: Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF
Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF Open
BACKGROUND: The TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) found no significant difference in all-cause mortality or hospitalization among patients randomized to a strategy of torsemide versus…
View article: Temporal Trends in Substance Use and Cardiovascular Disease–Related Mortality in the United States
Temporal Trends in Substance Use and Cardiovascular Disease–Related Mortality in the United States Open
Background There are limited data on substance use (SU) and cardiovascular disease (CVD)–related mortality trends in the United States. We aimed to evaluate SU+CVD–related deaths in the United States using the Centers for Disease Control a…
View article: Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure
Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure Open
View article: Bundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure
Bundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure Open
Importance The Centers for Medicare & Medicaid Services (CMS) Bundled Payments for Care Improvement (BPCI) program was launched in 2013 with a goal to improve care quality while lowering costs to Medicare. Objective To compare chan…